Skip to main content
SpringerLink
Log in

Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

A meta-analysis was performed to evaluate the correlation between single-nucleotide polymorphisms (SNPs) and risk of statin-induced myopathy (SIM).

Methods

We retrieved the studies published on SIM until April 2019 from the PubMed, Embase, and Cochrane Library databases. We collected data from 32 studies that analyzed 10 SNPs in five genes and included 21,692 individuals and nine statins.

Results

The analysis of the heterozygous (p = 0.017), homozygous (p = 0.002), dominant (p = 0.005), and recessive models (p = 0.009) of SLCO1B1 rs4149056 showed that this SNP increases the risk of SIM. Conversely, heterozygous (p = 0.048) and dominant models (p = 0.030) of SLCO1B1 rs4363657 demonstrated that this SNP is associated with a reduced risk of SIM. Moreover, an increased risk of SIM was predicted for carriers of the rs4149056 C allele among simvastatin-treated patients, whereas carriers of the GATM rs9806699 A allele among rosuvastatin-treated patients had a lower risk of SIM.

Conclusion

The meta-analysis revealed that the rs4149056 and rs4363657 SNPs in SLCO1B1 and the rs9806699 SNP in GATM are correlated with the risk of SIM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

References

  1. Savarese G, Gotto AM, Jr., Paolillo S, D’Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P (2013) Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. Journal of the American College of Cardiology 62 (22):2090-2099. doi:https://doi.org/10.1016/j.jacc.2013.07.069

  2. Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, Hubacek JA, Ceska R (2014) Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 63(Suppl 3):S327–S334

    Article  CAS  PubMed  Google Scholar 

  3. Stalenhoef A (2015) Coenzyme Q10 and statin-related myopathy. Drug Ther Bull 53(5):54–56. https://doi.org/10.1136/dtb.2015.5.0325

    Article  Google Scholar 

  4. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, European Atherosclerosis Society Consensus P (2015) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European heart journal 36 (17):1012-1022. doi:https://doi.org/10.1093/eurheartj/ehv043

  5. Needham M, Mastaglia FL (2014) Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 24(1):4–15. https://doi.org/10.1016/j.nmd.2013.09.011

    Article  CAS  PubMed  Google Scholar 

  6. Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, Xie QF, Zhang XD, Cui YM (2018) Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 18(6):721–729. https://doi.org/10.1038/s41397-018-0054-0

    Article  CAS  PubMed  Google Scholar 

  7. Hou Q, Li S, Li L, Li Y, Sun X, Tian H (2015) Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine 94(37):e1268. https://doi.org/10.1097/MD.0000000000001268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Canestaro WJ, Austin MA, Thummel KE (2014) Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med 16(11):810–819. https://doi.org/10.1038/gim.2014.41

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Su J, Xu H, Yang J, Yu Q, Yang S, Zhang J, Yao Q, Zhu Y, Luo Y, Ji L, Zheng Y, Yu J (2015) ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis 14:122. https://doi.org/10.1186/s12944-015-0114-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012. https://doi.org/10.1001/jama.283.15.2008

    Article  CAS  PubMed  Google Scholar 

  11. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z

    Article  PubMed  Google Scholar 

  12. Chen J, Chatterjee N (2007) Exploiting Hardy-Weinberg equilibrium for efficient screening of single SNP associations from case-control studies. Hum Hered 63(3-4):196–204. https://doi.org/10.1159/000099996

    Article  PubMed  Google Scholar 

  13. Areeshi MY, Mandal RK, Panda AK, Bisht SC, Haque S (2013) CD14 -159 C>T gene polymorphism with increased risk of tuberculosis: evidence from a meta-analysis. PloS one 8(5):e64747. https://doi.org/10.1371/journal.pone.0064747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bai X, Zhang B, Wang P, Wang GL, Li JL, Wen DS, Long XZ, Sun HS, Liu YB, Huang M, Zhong SL (2019) Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin 40(4):492–499. https://doi.org/10.1038/s41401-018-0013-y

    Article  CAS  PubMed  Google Scholar 

  15. Bakar NS, Neely D, Avery P, Brown C, Daly AK, Kamali F (2018) Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: a case-control study. Clinical pharmacology and therapeutics 104(1):178–187. https://doi.org/10.1002/cpt.887

    Article  CAS  PubMed  Google Scholar 

  16. Alghalyini B, El Shamieh S, Salami A, Visvikis Siest S, Fakhoury HM, Fakhoury R (2018) Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metab Pers Ther 33(1):41–47. https://doi.org/10.1515/dmpt-2017-0030

    Article  CAS  PubMed  Google Scholar 

  17. KS M, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, Abelega NU, Carr D, Bloch K, Hallberg P, Yue QY, Pearson ER, Colhoun HM, Morris AD, Dow E, George J, Pirmohamed M, Ridker PM, ASF D, Alfirevic A, Wadelius M, Maitland-van der Zee AH, Chasman DI, CNA P, Consortium P-A (2017) A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European heart journal 38(48):3569–3575. https://doi.org/10.1093/eurheartj/ehx467

    Article  CAS  Google Scholar 

  18. Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M, Lai WH, Ren B, Zhong SL (2017) SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 73(11):1409–1416. https://doi.org/10.1007/s00228-017-2318-z

    Article  CAS  PubMed  Google Scholar 

  19. Hubacek JA, Adamkova V, Zlatohlavek L, Steiner-Mrazova L, Vrablik M (2017) COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. Drug Metab Pers Ther 32(4):177–182. https://doi.org/10.1515/dmpt-2017-0027

    Article  CAS  PubMed  Google Scholar 

  20. Ovesjo ML, Skilving I, Bergman P, Rane A, Ekstrom L, Bjorkhem-Bergman L (2016) Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol 118(3):214–218. https://doi.org/10.1111/bcpt.12482

    Article  CAS  PubMed  Google Scholar 

  21. Khine H, Yuet WC, Adams-Huet B, Ahmad Z (2016) Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J 179:1–9. https://doi.org/10.1016/j.ahj.2016.05.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Luzum JA, Kitzmiller JP, Isackson PJ, Ma C, Medina MW, Dauki AM, Mikulik EB, Ochs-Balcom HM, Vladutiu GD (2015) GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab 21(4):622–627. https://doi.org/10.1016/j.cmet.2015.03.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hubacek JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, Ceska R, Vrablik M (2015) SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 21:1454–1459. https://doi.org/10.12659/MSM.893007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, Collins R, Wilke RA, Nickerson DA, Stephens M, Krauss RM (2013) A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502(7471):377–380. https://doi.org/10.1038/nature12508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carr DF, Alfirevic A, Johnson R, Chinoy H, van Staa T, Pirmohamed M (2014) GATM gene variants and statin myopathy risk. Nature 513(7518):E1. https://doi.org/10.1038/nature13628

    Article  CAS  PubMed  Google Scholar 

  26. Floyd JS, Bis JC, Brody JA, Heckbert SR, Rice K, Psaty BM (2014) GATM locus does not replicate in rhabdomyolysis study. Nature 513(7518):E1–E3. https://doi.org/10.1038/nature13629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, Marino F, Cosentino M (2014) Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 70(5):539–547. https://doi.org/10.1007/s00228-014-1661-6

    Article  CAS  PubMed  Google Scholar 

  28. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM (2013) Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 165(6):1008–1014. https://doi.org/10.1016/j.ahj.2013.01.025

    Article  CAS  PubMed  Google Scholar 

  29. Carr DF, O’Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M (2013) SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clinical pharmacology and therapeutics 94(6):695–701. https://doi.org/10.1038/clpt.2013.161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC (2012) SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 68(3):273–279. https://doi.org/10.1007/s00228-011-1125-1

    Article  CAS  PubMed  Google Scholar 

  31. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR (2012) Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 12(3):233–237. https://doi.org/10.1038/tpj.2010.92

    Article  CAS  PubMed  Google Scholar 

  32. Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL (2011) Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 104(1-2):167–173. https://doi.org/10.1016/j.ymgme.2011.07.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM (2011) Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 21(5):280–288. https://doi.org/10.1097/FPC.0b013e328343dd7d

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Isackson PJ, Ochs-Balcom HM, Ma C, Harley JB, Peltier W, Tarnopolsky M, Sripathi N, Wortmann RL, Simmons Z, Wilson JD, Smith SA, Barboi A, Fine E, Baer A, Baker S, Kaufman K, Cobb B, Kilpatrick JR, Vladutiu GD (2011) Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle & nerve 44(4):531–538. https://doi.org/10.1002/mus.22115

    Article  CAS  Google Scholar 

  35. Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L (2011) The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol 5(2):91–96. https://doi.org/10.1016/j.jacl.2011.01.001

    Article  PubMed  Google Scholar 

  36. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN (2011) Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clinical pharmacology and therapeutics 89(2):210–216. https://doi.org/10.1038/clpt.2010.255

    Article  CAS  PubMed  Google Scholar 

  37. Puccetti L, Ciani F, Auteri A (2010) Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211(1):28–29. https://doi.org/10.1016/j.atherosclerosis.2010.02.026

    Article  CAS  PubMed  Google Scholar 

  38. Linde R, Peng L, Desai M, Feldman D (2010) The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2(2):77–84. https://doi.org/10.4161/derm.2.2.13509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Search Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. The New England journal of medicine 359(8):789–799. https://doi.org/10.1056/NEJMoa0801936

    Article  Google Scholar 

  40. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR (2007) Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 55(4):310–317. https://doi.org/10.1016/j.phrs.2006.12.009

    Article  CAS  PubMed  Google Scholar 

  41. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA (2007) Genetic determinants of statin intolerance. Lipids Health Dis 6:7. https://doi.org/10.1186/1476-511X-6-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ (2007) CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 17(9):695–707. https://doi.org/10.1097/FPC.0b013e328012d0a9

    Article  CAS  PubMed  Google Scholar 

  43. Fisher NM, Meksawan K, Limprasertkul A, Isackson PJ, Pendergast DR, Vladutiu GD (2007) Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation. J Inherit Metab Dis 30(3):388–399. https://doi.org/10.1007/s10545-007-0449-6

    Article  CAS  PubMed  Google Scholar 

  44. Wilke RA, Moore JH, Burmester JK (2005) Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 15(6):415–421

    Article  CAS  PubMed  Google Scholar 

  45. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clinical Pharmacology and Therapeutics 78(5):551–558. https://doi.org/10.1016/j.clpt.2005.08.003

    Article  CAS  PubMed  Google Scholar 

  46. Smith NF, Figg WD, Sparreboom A (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1(3):429–445. https://doi.org/10.1517/17425255.1.3.429

    Article  CAS  PubMed  Google Scholar 

  47. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical pharmacology and therapeutics 73(6):554–565. https://doi.org/10.1016/s0009-9236(03)00060-2

    Article  CAS  PubMed  Google Scholar 

  48. Norata GD, Tibolla G, Catapano AL (2014) Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol Res 88:107–113. https://doi.org/10.1016/j.phrs.2014.04.012

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by grants from the National Key R&D Program of China (No. 2016YFC0904900), the National Natural Science Foundation (No. 81872940 and No. 81973395) of China, the Natural Science Foundation of Beijing Municipality (No. 7171012), and the National Science and Technology Major Projects for “Major New Drugs Innovation and Development” of China (No. 2017ZX09304028 and No. 2017ZX09101001).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Peking University First Hospital, Beijing, 100034, China

    Qian Xiang, Xiao-Dan Zhang, Guang-Yan Mu, Zhe Wang, Zhi-Yan Liu, Qiu-Fen Xie, Kun Hu, Zhuo Zhang, Ling-Yue Ma & Yi-Min Cui

  2. Department of Cardiology, Peking University First Hospital, Beijing, 100034, China

    Jie Jiang

  3. Beijing, China

    Yi-Min Cui

Authors
  1. Qian Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-Dan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang-Yan Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhe Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhi-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qiu-Fen Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ling-Yue Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jie Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yi-Min Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QX and XDZ wrote the manuscript; QX and YMC designed the research; QFX, KH, ZZ, LM, and JJ performed the research; GYM, ZW, and ZYL analyzed the data; ZYL and XDZ contributed new reagents/analytical tools.

Corresponding author

Correspondence to Yi-Min Cui.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethics approval

Not applicable

Consent to participate

Not applicable

Consent for publication

Not applicable

Code availability

Not applicable

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(DOCX 16 kb)

ESM 2

(DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiang, Q., Zhang, XD., Mu, GY. et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol 77, 569–581 (2021). https://doi.org/10.1007/s00228-020-03029-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-03029-1

Keywords

Search

Navigation